The primary objective of the multicenter study is to compare the safety, tolerability and efficacy of SB204269 with placebo as add on therapy in patients with refractory simple or complex partial seizures. Another objective is to gather population pharmacokinetic for SB204269 as adjunct therapy in patients. The study consists of 3 phases: Baseline, Double blind, and long term extension phases. Throughout the study physical and neurological exams will be performed. SB204269 can cause mild side effects reversible by lowering dosage.
Showing the most recent 10 out of 565 publications